Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis
Interventions: Alicaforsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ulcerative Colitis
Interventions: Mirikizumab SC, Mirikizumab IV, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 57
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more

Conditions: Diabetic Foot Ulcer
Interventions: Affinity human amniotic membrane; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Miami Lakes, Florida • North Miami Beach, Florida • Ford City, Pennsylvania + 3 more

Conditions: Diabetic Foot Ulcers
Interventions: type of footwear, collagen dressing with and without silver; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Vedolizumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetic Foot Ulcer
Interventions: NuShield; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 6 more

Conditions: Infected Corneal Ulcers, Bacterial Keratitis, Corneal Ulcer, Childhood Blindness
Interventions: Povidone-Iodine; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 1 Month and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Torrance, California

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Dothan, Alabama • Lancaster, California • Orange, California + 39 more

Conditions: Oral Lichen Planus
Interventions: Clobetasol Propionate; Drug
Lead sponsor: Dermtreat; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more

Conditions: Colitis, Ulcerative
Interventions: Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more

Conditions: Diabetic Foot Ulcers, Osteomyelitis
Interventions: DFU; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Venous Leg Ulcer
Interventions: Marine polysaccharide dressing, Carboxymethylcellulose dressing; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Fresno, California • Selma, California • Boston, Massachusetts + 2 more

Conditions: Diabetic Foot Infections
Interventions: Bisphosphocin Nu-3, Placebo; Drug
Lead sponsor: Lakewood-Amedex Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Oldsmar, Florida • Franklin, Tennessee

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions: PN-943, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 31
States / cities: Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions: Fecal Microbiota Transplantation, Psyllium Husk Powder; Drug · Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Standard of care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetic Foot Ulcer
Interventions: Derm-Maxx; Other
Lead sponsor: Capsicure, LLC; Network
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: Athens, Alabama • Encino, California • Hollywood, Florida + 8 more

Conditions: Diabetic Foot Ulcer
Interventions: COMS One device, Sham device; Device
Lead sponsor: Piomic Medical; Industry
Eligibility: 22 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more

Conditions: Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
Interventions: Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: PolarityTE; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Martinsville, Virginia

Conditions: Venous Leg Ulcer, Venous Stasis Ulcer
Interventions: No HP802 Treatment, No HP802 Vehicle Treatment; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 29
States / cities: Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more

Conditions: Diabetic Foot Ulcer, Infection
Interventions: PluroGel N, PluroGel; Drug
Lead sponsor: PluroGen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 8 more

Conditions: Pyoderma Gangrenosum
Interventions: vilobelimab, Placebo; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more

Search by objective public record fields.

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Affinity Prospective Diabetic Foot Trial Crossover Group

Developing a Diabetic Foot Ulcer Protocol

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository

A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)

Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

SkinTE™ in the Treatment of Diabetic Foot Wounds

Safety Follow-Up to HP 802-247-09-015

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum